"uBiome is excited to be a part of JPM and we look forward to discussing the implications of the microbiome for healthcare with leaders in the industry. The microbiome is essential for human health, and JPM is the ideal place to continue this dialogue." - Jessica Richman, PhD, co-founder, CEO
SAN FRANCISCO (PRWEB) December 27, 2018
uBiome, the leader in microbial genomics, announces the second annual Microbiome Conference at JPM as part of the JP Morgan 37th Annual Healthcare Conference in San Francisco, which brings together industry leaders, emerging fast-growth companies, innovative scientists and physicians, and members of the investment community.
Since its origin in 1983, the JP Morgan Healthcare Conference has grown to welcome thousands of investors and companies from new startups to those with more than $300 billion in market capital, encompassing the entire global healthcare landscape including pharmaceutical firms, healthcare service providers, profit and not-for-profits, and medical device companies.
The microbiome has a profound effect on human health, including synthesizing vitamins, metabolizing nutrients, impacting immune response, and interacting with hormones to affect human health. Given that recent research suggests microbes influence body systems and various health conditions, understanding and further manipulating these interactions may allow for better management and treatment of conditions.
“uBiome is excited to be a part of JPM and we look forward to discussing the implications of the microbiome for healthcare with leaders in the industry,” Dr. Jessica Richman, PhD, co-founder and CEO of uBiome said, “The microbiome is essential for human health, and JPM is the ideal place to continue this dialogue.”
To learn more about uBiome’s efforts, please visit https://ubiome.com/about-us/.
Founded in 2012, uBiome is the leader in microbial genomics. The Company’s mission is to advance the science of the microbiome and make it useful to people. uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets. uBiome has filed for over 250 patents on its technology, which includes sample preparation, computational analysis, molecular techniques, as well as diagnostic and therapeutic applications.
uBiome’s commercial products include SmartGut™, the world’s first sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn’s Disease, and ulcerative colitis; SmartJane™, the first sequencing-based women’s health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; and Explorer™, a health and wellness product to understand the role that food and lifestyle can play in wellness.
uBiome’s platform has been used by hundreds of thousands of consumers, patients, and doctors and more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney.
Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company’s Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018, as well as a Technology Pioneer from the World Economic Forum in 2018. For more information, visit http://www.uBiome.com.